Drug intelligence / Profile preview

anastrozole + exemestane + saracatinib

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of aromatase inhibitors (anastrozole or exemestane) with saracatinib (AZD0530), a dual Src/Abl kinase inhibitor. This combination was studied for hormone receptor-positive metastatic breast cancer in postmenopausal women, with the aim of preventing or overcoming endocrine resistance. Saracatinib enhances the anti-proliferative effect of endocrine agents in breast cancer models and also inhibits bone resorption via osteoclast activity.

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on anastrozole + exemestane + saracatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anastrozole + exemestane + saracatinib.

Explore the full profile